AI-Generated Drug Rentosertib Shows Potential to Slow Aging in Early Data

Early data suggest that rentosertib — a drug discovered and designed by artificial intelligence and already in final-stage human trials — could slow biological aging, Insilico Medicine says, in findings published in Nature Biotechnology and reported Monday by The New York Times, Bloomberg and The Wall Street Journal.

The announcement marks the first time an AI-developed drug has produced human evidence touching directly on the biology of aging, and it lands as the AI drug discovery race moves from pitched demos to late-stage clinical reality. Bloomberg reported the biotech's claim that the study shows the drug reversing aging markers, while The New York Times characterized the early data as indicating the drug could slow aging itself.

From Lung Disease Drug to Longevity Candidate

Rentosertib was not conceived as an anti-aging pill. It targets idiopathic pulmonary fibrosis (IPF), a progressive and often fatal lung disease with limited treatment options. But its mechanism is what has drawn the longevity world's attention: the drug inhibits TNIK, an enzyme that sits at the intersection of several fibrosis-driving signaling pathways, including TGF-β and Wnt.

TNIK also plays a role in the senescence-associated secretory phenotype, or SASP — the cocktail of inflammatory signals that aging cells pump out and that damages surrounding tissue. Preclinical studies have shown rentosertib has senomorphic properties, meaning it modulates the harmful signaling of senescent cells rather than killing them outright. Cellular senescence is implicated in a broad range of age-related diseases, from neurodegeneration to cardiovascular disease and cancer, which is why Insilico has been explicit about viewing the drug's mechanism through an aging biology lens as well as a fibrosis one.

The AI Discovery Pipeline Behind It

The drug's origin story is a proof of concept for the entire AI drug discovery movement. Insilico Medicine used its proprietary platforms — PandaOmics for target identification and Chemistry42 for molecular generation — to identify TNIK as a novel target and then design a candidate molecule against it, a process the company says took roughly 18 months from target discovery to preclinical candidate.

That timeline, compressed against the five to six years a conventional discovery campaign typically consumes, is the core argument for AI-first drug development, and rentosertib is its most advanced exhibit: the first oral TNIK inhibitor to reach clinical trials anywhere in the world.

What the Earlier Human Data Showed

The new aging-related findings build on results that already made rentosertib notable. In a Phase IIa trial, results of which were published in Nature Medicine in June 2025, patients receiving the 60 mg dose saw a mean increase of 98.4 mL in forced vital capacity — a standard measure of lung function — over 12 weeks, while the placebo group declined by 20.3 mL. In a disease where existing therapies such as nintedanib and pirfenidone merely slow decline, a drug that improves lung function while maintaining a manageable safety profile would represent a genuine shift in the treatment paradigm.

Phase III Is Already Underway

Rentosertib entered Phase III testing on July 7, 2026, across 47 centers in China, with approximately 320 patients enrolled in a randomized, double-blind, placebo-controlled study. Key investigators include Zuojun Xu, Chang Chen, and Nanshan Zhong, one of China's most prominent respiratory medicine specialists.

As is typical for chronic disease trials, the Phase III readout is expected to take several years. But Insilico has said the trial will collect biomarker data on SASP factors and senescence markers along the way, potentially yielding some of the most detailed human evidence yet on whether pharmacologically targeting the biology of aging is feasible.

The company's financial position gives it room to run the trial. Insilico has forecast a positive result for the first half of 2026, citing its pipeline — rentosertib chief among its assets — as a key driver.

Cautious Optimism From the Company's Leadership

Insilico's co-CEO told The Wall Street Journal the company has bigger hopes for the drug than fibrosis alone — namely, that it can eventually be shown to reverse aging itself. That ambition remains unproven: no drug has ever been approved as an anti-aging therapy, and regulators have no established pathway for approving one, since aging is not classified as a disease.

What the Nature Biotechnology publication offers is intermediate evidence — measurable changes in aging-related markers — rather than a demonstrated extension of human lifespan or healthspan. The gap between those two things is where most longevity drug programs have foundered.

Why It Matters

If rentosertib's Phase III data hold up, the result would validate two propositions at once: that AI-designed molecules can clear the highest bar in medicine, and that drugs developed for one disease can be repurposed against aging biology more broadly. Either outcome would reshape how the pharmaceutical industry allocates its research budgets.

For now, the appropriate posture is the one the drug's own trial design embodies: measure carefully, in humans, over years. The aging-marker data are an early signal, not a verdict — but they are an early signal attached to a drug already deep in the final stage of clinical testing, which puts it years ahead of most longevity science.

Stay Ahead of AI

For more on how artificial intelligence is transforming medicine, science, and daily life, follow our breaking AI news coverage. We track the research, the companies, and the policies shaping the field in real time.

Read more AI news →